Pharmafile Logo
Pharmafocus logo
Advanced Search

Amgen

Showing 15 posts of 214 posts found.

amgen_hq

Amgen’s patent win upheld against Sanofi-Regeneron

January 4, 2017
Medical Communications, Research and Development Amgen, Regeneron, Sanofi, patent

In March 2016, Amgen won two major patent cases against Sanofi and Regeneron over their drug, Praleunt, after it was …

News
humira_abbott_

Humira biosimilar proves efficacy in Phase 3 trial

November 30, 2016
Research and Development AbbVie, Amgen, FDA, Humira, M923, Momenta

US-based biotechnology firm Momenta Pharmaceuticals has announced that its biosimilar version of Abbvie’s autoimmune drug Humira (adalimumab) – currently the …

News
amgen_hq

Amgen boosted in race to market for migraine drug

November 17, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Novartis, erenumab, migraine, phase III

Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …

News
amgen_hq

NICE turns down Amgen’s multiple myeloma drug

November 9, 2016
Research and Development, Sales and Marketing Amgen, Kyprolis, NICE

Amgen has seen its drug Kyprolis (carfilzomib) rejected by NICE for its routine use in the treatment of multiple myeloma …

News
amgen_hq

FDA approves first therapy for paediatric psoriasis treatment

November 7, 2016
Sales and Marketing Amgen, Enbrel, paediatric, psoriasis

Amgen’s Enbrel has been given approval by the FDA for expanded use to treat children with chronic moderate-to-severe plaque psoriasis. …

News
ema_inside

EMA opens clinical trial data to public

October 25, 2016
Manufacturing and Production Amgen, AstraZeneca, EMA, EU, Kyprolis, clinical reports, clinical trials

The European Medicine Agency has begun to release to the public data on clinical trial via their own website. The …

News
amgen_hq

Amgen’s Kyprolis disappoints in Phase III trial

September 27, 2016
Manufacturing and Production, Research and Development Amgen, Kyprolis, phase III

Amgen was relying on the results of the trial to justify its $10.4 billion purchase of Onyx Pharmaceuticals, acquiring Kyprolis …

News
humira_abbott__4

FDA gives the green light to the first Humira biosimilar

September 26, 2016
Sales and Marketing AbbVie, Amgen, Amjevita, FDA, Humira

Amgen’s Amjevita has been given the go ahead for all eligible indications of its reference product, including moderate-to-severe rheumatoid arthritis, …

News
amgen_hq

Positive Phase III results for Amgen’s Repatha for coronary artery disease

September 21, 2016
Research and Development Amgen, Phase III trial, Repatha

Amgen has announced that its monoclonal antibody Repatha (evolocumab) achieved positive Phase III results for the treatment of coronary artery …

News
amgen_flag

Amgen’s leukaemia treatment given FDA thumbs up for use in paediatric patients

September 2, 2016
Medical Communications, Sales and Marketing Amgen, FDA, blincyto, leukaemia

Amgen has announced that the FDA has approved the supplemental Biologics License Application for Blincyto (blinatumomab) in the treatment of …

News
amgen_hq

Amgen’s Prolia achieves positive top-line Phase III results after 12 months

August 30, 2016
Manufacturing and Production, Research and Development Amgen, Prolia, denosumab, phase III

Amgen has announced that its drug Prolia (denosumab) generated positive Phase III results investigating its safety and efficacy in patients …

News
amgen_flag

FDA says no to Amgen’s Parsabiv

August 25, 2016
Research and Development, Sales and Marketing Amgen, FDA, par

Amgen has announced that the US Food and Drug Administration (FDA) has issued a complete response letter rejecting Parsabiv (etelcalcetide) …

News
praluent_75mg_pen_box_hr

Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds

August 17, 2016
Research and Development, Sales and Marketing Amgen, QALY, Regeneron, Repatha, Sanofi, cost effective, cost-effective, praluent

A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …

News
imlygic_amgen

NICE recommends Amgen’s Imlygic for advanced skin cancer

August 9, 2016
Manufacturing and Production, Sales and Marketing Amgen, Imlygic, NICE, skin cancer

NICE has published its final draft guidance recommending Amgen’s Imlygic (talimogene laherparepvec) for the treatment of advanced melanoma in adults …

News
humira_abbott_

AbbVie files lawsuit against Amgen over Humira copy

August 8, 2016
Research and Development, Sales and Marketing AbbVie, Amgen, FDA, Humira, rheumatoid arthritis

Abbvie has filed a patent infringement lawsuit against Amgen over the latter firm’s copy of its Humira (adalimumab) rheumatoid arthritis …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023